Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy

Ding, Guo-Bin; Zhu, Chenchen; Wang, Qian; Cao, Huiyan; Li, Binchun; Yang, Peng; Stauber, Roland H.; Nie, Guangjun; Li, Zhuoyu

doi:10.1016/j.bioactmat.2022.02.001

Cited by 10 publications

(6 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to KEGG pathway analysis, NPM1 co-expression is primarily associated with Ribosomes. It has been found that the above biological functions and pathways play an important role in the occurrence and development of tumors, according to some scholars ( Ruggero and Pandolfi, 2003 ; Ding et al, 2022 ). These findings suggest that NPM1’s co-expression network plays a critical role in the formation and progression of tumors.…”

Section: Discussionmentioning

confidence: 99%

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Liu

Liu²,

Zeng³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: NPM1 is highly expressed in a variety of solid tumors and promotes tumor development. However, there are few comprehensive studies on NPM1 analysis in gastrointestinal cancer.Methods: We used bioinformatics tools to study the expression difference of NPM1 between gastrointestinal cancer and control group, and analyzed the relationship between its expression level and the diagnosis, prognosis, functional signaling pathway, immune infiltration, m6A and cuproptosis related genes of gastrointestinal cancer. At the same time, the expression difference of NPM1 between esophageal carcinoma (ESCA) samples and control samples was verified by in vitro experiments.Results: NPM1 was overexpressed in gastrointestinal cancer. In vitro experiments confirmed that the expression of NPM1 in ESCA samples was higher than that in normal samples. The expression of NPM1 has high accuracy in predicting the outcome of gastrointestinal cancer. The expression of NPM1 is closely related to the prognosis of multiple gastrointestinal cancers. Go and KEGG enrichment analysis showed that NPM1 co-expressed genes involved in a variety of biological functions. NPM1 expression is potentially associated with a variety of immune cell infiltration, m6A and cuproptosis related genes in gastrointestinal cancers.Conclusion: NPM1 can be used as a diagnostic and prognostic marker of gastrointestinal cancer, which is related to the immune cell infiltration and the regulation of m6A and cuproptosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Liu

Liu²,

Zeng³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Even a large, polar protein payload, the 30 kDa glycoprotein gelonin, was successfully delivered by pHLIP to the cytoplasm ( Ding et al, 2022 ). Gelonin, is a type I ribosome inactivating protein phytotoxin, which inhibits protein synthesis by cleaving Adenine 4,324 of the 28S ribosomal RNA, resulting in cell death ( Shin et al, 2014 ).…”

Section: Intracellular Delivery Of Therapeutic Payloads By Phlipmentioning

confidence: 99%

Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides

Reshetnyak,

Andreev,

Engelman

2024

Front. Pharmacol.

View full text Add to dashboard Cite

The family of pH (Low) Insertion Peptides (pHLIP) comprises a tumor-agnostic technology that uses the low pH (or high acidity) at the surfaces of cells within the tumor microenvironment (TME) as a targeted biomarker. pHLIPs can be used for extracellular and intracellular delivery of a variety of imaging and therapeutic payloads. Unlike therapeutic delivery targeted to specific receptors on the surfaces of particular cells, pHLIP targets cancer, stromal and some immune cells all at once. Since the TME exhibits complex cellular crosstalk interactions, simultaneous targeting and delivery to different cell types leads to a significant synergistic effect for many agents. pHLIPs can also be positioned on the surfaces of various nanoparticles (NPs) for the targeted intracellular delivery of encapsulated payloads. The pHLIP technology is currently advancing in pre-clinical and clinical applications for tumor imaging and treatment.

show abstract

“…The results of the first human experiment showed that the fluorescence-guided imaging based on the NIR fluorescence probe targeting CD44v6 is a safe and effective method, which can improve the detection rate of BCa, and may enable complete resection to prevent recurrence ( 74 ). The pH-low insertion peptide (pHLIP) is a C-helix derived from the bacteriorhodopsin protein that targets the acidic microenvironment in the tumor matrix ( 75 ). pHLIP conjugated to a NIR fluorophore can be used for ex vivo fluorescence imaging of BCa.…”

Section: Erbt Combined With Enhanced Imaging Technologymentioning

confidence: 99%

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective

Yang

Wang

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

According to the guidelines, transurethral resection of bladder tumor (TURBT) followed by intravesical therapy remains the standard strategy for the management of non-muscle invasive bladder cancer (NMIBC). However, even if patients receive standard strategy, the risk of postoperative recurrence and progression is high. From the clinical perspective, the standard strategy needs to be optimized and improved. Compared to conventional TURBT, the technique of en bloc resection of bladder tumor (ERBT) removes the tumor tissue in one piece, thus following the principles of cancer surgery. Meanwhile, the integrity and spatial orientation of tumor tissue is protected during the operation, which is helpful for pathologists to make accurate histopathological analysis. Then, urologists can make a postoperative individualized treatment plan based on the patient’s clinical characteristics and histopathological results. To date, there is no strong evidence that NMIBC patients treated with ERBT achieve better oncological prognosis, which indicates that ERBT alone does not yet improve patient outcomes. With the development of enhanced imaging technology and proteogenomics technology, en bloc resection combined with these technologies will make it possible to achieve precise diagnosis and treatment of bladder cancer. In this review, the authors analyze the current existing shortcomings of en bloc resection and points out its future direction, in order to promote continuous optimization of the management strategy of bladder cancer.

show abstract

Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy

Cited by 10 publications

References 65 publications

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Nucleophosmin 1 is a prognostic marker of gastrointestinal cancer and is associated with m6A and cuproptosis

Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective

Contact Info

Product

Resources

About